{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:27:23Z","timestamp":1794587243297,"version":"4.9.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The increasing age of patients with rheumatoid arthritis (RA) has heightened concern regarding osteoporosis and bone fragility. While bone loss in RA has been well studied, less is known about long-term changes in bone quality-related markers under different disease activity states and antirheumatic treatments. In this retrospective observational study, 25 patients with RA aged\u2005\u2265\u200550 years were followed for up to 2 years, during which serum bone matrix and turnover markers, including pentosidine, tartrate-resistant acid phosphatase-5b, and total procollagen type 1 N-terminal propeptide, were measured every 6 months. Patients were classified into a Remission group (Disease Activity Score in 28 joints based on C-reactive protein\u2005&lt;\u20052.3) and a High\/Moderate\/Low Disease Activity (H\/M\/LDA) group (Disease Activity Score in 28 joints based on C-reactive protein\u2005\u2265\u20052.3). Longitudinal changes were evaluated using linear mixed-effects models with group-by-time interaction terms. Additional treatment-based comparisons were performed within the Remission group between patients treated without biological\/targeted synthetic disease-modifying antirheumatic drugs (non-b\/tsDMARDs) and those treated with b\/tsDMARDs, with additional adjustment for baseline age and estimated glomerular filtration rate. At baseline, serum pentosidine levels were higher and serum total procollagen type 1 N-terminal propeptide levels were lower in the H\/M\/LDA group than in the Remission group, whereas tartrate-resistant acid phosphatase-5b levels did not differ. Linear mixed-effects analyses showed no significant group-by-time interactions between the Remission and H\/M\/LDA groups. Within the Remission group, serum pentosidine increased at later time points in patients treated with non-b\/tsDMARDs, whereas no clear increase was observed in those treated with b\/tsDMARDs. However, after adjustment for baseline age and estimated glomerular filtration rate, the overall group-by-time interaction for pentosidine was no longer statistically significant. These findings suggest that bone quality-related deterioration may remain a concern even in RA patients in clinical remission. However, because the adjusted overall interaction was not statistically significant, the observed association between b\/tsDMARD use and longitudinal pentosidine changes should be considered exploratory and requires further validation in larger studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049282","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:00:06Z","timestamp":1782108006000},"page":"e49282","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Long-term longitudinal changes in bone matrix and turnover markers in rheumatoid arthritis: A retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-5667","authenticated-orcid":false,"given":"Yu","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, The Jikei University Daisan Hospital, 4-11-1 Izumihoncho, Komae, Tokyo, Japan"},{"name":"Department of Orthopaedic Surgery, The Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6610-901X","authenticated-orcid":false,"given":"Kazuhiro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The Jikei University Daisan Hospital, 4-11-1 Izumihoncho, Komae, Tokyo, Japan"},{"name":"Department of Orthopaedic Surgery, The Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinako","family":"Okabe","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hadano","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The Jikei University Daisan Hospital, 4-11-1 Izumihoncho, Komae, Tokyo, Japan"},{"name":"Department of Orthopaedic Surgery, The Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261113","first-page":"1","article-title":"Rheumatoid arthritis.","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Prim"},{"key":"R2-20261113","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the global burden of disease study 2017.","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R3-20261113","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the national database of health insurance claims and specific health checkups of Japan.","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"R4-20261113","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study.","volume":"20","author":"Kato","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"R5-20261113","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00198-009-1066-z","article-title":"Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.","volume":"21","author":"Saito","year":"2010","journal-title":"Osteoporos Int"},{"key":"R6-20261113","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3390\/ijms23052871","article-title":"inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments.","volume":"23","author":"Maeda","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R7-20261113","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/jcm10061241","article-title":"Managing osteoporosis and joint damage in patients with rheumatoid arthritis: an overview.","volume":"10","author":"Tanaka","year":"2021","journal-title":"J Clin Med"},{"key":"R8-20261113","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy.","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R9-20261113","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0004563217733500","article-title":"Increased serum concentrations of N\u025b-carboxymethyllysine are related to the presence and the severity of rheumatoid arthritis.","volume":"55","author":"Knani","year":"2018","journal-title":"Ann Clin Biochem"},{"key":"R10-20261113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14397595.2017.1369491","article-title":"RANKL: a therapeutic target for bone destruction in rheumatoid arthritis.","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R11-20261113","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S8756-3282(97)00023-9","article-title":"Methotrexate maintains bone mass by preventing both a decrease in bone formation and an increase in bone resorption in adjuvant-induced arthritic rats.","volume":"20","author":"Segawa","year":"1997","journal-title":"Bone"},{"key":"R12-20261113","first-page":"1305","article-title":"Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study.","volume":"31","author":"Di Munno","year":"2004","journal-title":"J Rheumatol"},{"key":"R13-20261113","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/s10165-007-0607-6","article-title":"Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis.","volume":"17","author":"Kageyama","year":"2007","journal-title":"Mod Rheumatol"},{"key":"R14-20261113","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF\u03baB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.","volume":"65","author":"Vis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R15-20261113","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.2007.076604","article-title":"Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.","volume":"67","author":"Chopin","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R16-20261113","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00198-021-05871-0","article-title":"Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis.","volume":"32","author":"Hamar","year":"2021","journal-title":"Osteoporos Int"},{"key":"R17-20261113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-020-02340-7","article-title":"The Janus kinase 1\/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.","volume":"22","author":"Thudium","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R18-20261113","first-page":"73","article-title":"Reduction of oxidative stress marker levels by anti-TNF-\u03b1 antibody, infliximab, in patients with rheumatoid arthritis.","volume":"26","author":"Kageyama","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"R19-20261113","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00296-007-0419-1","article-title":"Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis.","volume":"28","author":"Kageyama","year":"2008","journal-title":"Rheumatol Int"},{"key":"R20-20261113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2114\/jpa.23.19","article-title":"Calorie restricted diet and urinary pentosidine in patients with rheumatoid arthritis.","volume":"23","author":"Iwashige","year":"2004","journal-title":"J Physiol Anthropol Appl Human Sci"},{"key":"R21-20261113","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative.","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R22-20261113","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American college of physicians.","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"key":"R23-20261113","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/ard.2006.063834","article-title":"Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients.","volume":"66","author":"Matsui","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R24-20261113","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R25-20261113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endocr\/bqac126","article-title":"Osteoblast lineage cells-derived Sema3A regulates bone homeostasis independently of androgens.","volume":"163","author":"Yamashita","year":"2022","journal-title":"Endocrinology"},{"key":"R26-20261113","doi-asserted-by":"crossref","first-page":"10733","DOI":"10.3390\/ijms231810733","article-title":"Proton pump inhibitors and bone health: an update narrative review.","volume":"23","author":"Lespessailles","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R27-20261113","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s11033-021-06288-y","article-title":"Osteoblast role in the pathogenesis of rheumatoid arthritis.","volume":"48","author":"Berardi","year":"2021","journal-title":"Mol Biol Rep"},{"key":"R28-20261113","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling.","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat Med"},{"key":"R29-20261113","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.","volume":"54","author":"Van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R30-20261113","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3899\/jrheum.101196","article-title":"Arthritis increases the risk for fractures - results from the women\u2019s health initiative.","volume":"38","author":"Wright","year":"2011","journal-title":"J Rheumatol"},{"key":"R31-20261113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-020-02163-6","article-title":"Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.","volume":"22","author":"Gabay","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R32-20261113","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/dmr.5610070404","article-title":"Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia.","volume":"7","author":"Sell","year":"1991","journal-title":"Diabetes Metab Rev"},{"key":"R33-20261113","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1196\/annals.1333.082","article-title":"Advanced glycation end products and bone loss during aging.","volume":"1043","author":"Odetti","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"R34-20261113","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00223-006-0035-1","article-title":"Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls.","volume":"79","author":"Saito","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"R35-20261113","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00774-008-0878-9","article-title":"The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures.","volume":"26","author":"Shiraki","year":"2008","journal-title":"J Bone Miner Metab"},{"key":"R36-20261113","doi-asserted-by":"crossref","first-page":"e0163826","DOI":"10.1371\/journal.pone.0163826","article-title":"Plasma pentosidine and its association with mortality in patients with chronic kidney disease.","volume":"11","author":"MacHowska","year":"2016","journal-title":"PLoS One"},{"key":"R37-20261113","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1359\/jbmr.040820","article-title":"Bone fragility and collagen cross-links.","volume":"19","author":"Paschalis","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R38-20261113","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14397595.2018.1524998","article-title":"Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance.","volume":"29","author":"Harigai","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R39-20261113","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British society for rheumatology biologics register with special emphasis on risks in the elderly.","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R40-20261113","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3899\/jrheum.130901","article-title":"Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.","volume":"41","author":"Matsubara","year":"2014","journal-title":"J Rheumatol"},{"key":"R41-20261113","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3899\/jrheum.160012","article-title":"Safety of biologic agents in elderly patients with rheumatoid arthritis.","volume":"43","author":"Murota","year":"2016","journal-title":"J Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:00:14Z","timestamp":1794585614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":41,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049282","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2026-01-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}